Viridian Therapeutics, Inc. VRDN Issuance costs allocated to derivative liability
Issuance costs allocated to derivative liability at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept vrdn:DerivativeLiabilityIssuanceCosts.
The official record: Viridian Therapeutics, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s issuance costs allocated to derivative liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s issuance costs allocated to derivative liability?
- Viridian Therapeutics, Inc. (VRDN) reported issuance costs allocated to derivative liability of $437.75K in Q4 2025.
- What does issuance costs allocated to derivative liability mean?
- This represents the portion of transaction costs associated with issuing financial instruments that are classified as derivative liabilities. These costs are typically deferred and amortized over the life of the instrument or expensed as incurred depending on accounting standards. It provides insight into the friction costs associated with complex financing arrangements.